Evidence map›Paper›PMID 19796067›Full record

ReviewXenotransplantation

Current status of xenotransplantation and prospects for clinical application.

Richard N Pierson, Anthony Dorling, David Ayares, Michael A Rees, Jörg D Seebach, Jay A Fishman, Bernhard J Hering, David K C Cooper

Abstract readReview
In one paragraph

Review in Xenotransplantation. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers.

0numbers the graph read from it
0cells of the map it votes in
56citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

56 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Regulatory macrophages in solid organ xenotransplantation.Korean journal of transplantation · 2023
    Review
  10. Article
  11. Orthotopic Heart Auto-Transplantation in a Swine Model.World journal of cardiovascular surgery · 2022
    Article
  12. Progress toward Pig-to-Human Xenotransplantation.The New England journal of medicine · 2022
    Article
  13. Pig-to-baboon lung xenotransplantation: Extended survival with targeted genetic modifications and pharmacologic treatments.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2022
    Article
  14. Review
  15. Article
  16. CRISPR/Cas Technology in Pig-to-Human Xenotransplantation Research.International journal of molecular sciences · 2021
    Review
  17. Review
  18. Pig-to-human heart transplantation: Who goes first?American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2020
    Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Richard N PiersonDivision of Cardiac Surgery, Department of Surgery, University of Maryland, Baltimore VAMC, Baltimore, MD 21201, USA. rpierson@smail.umaryland.edu
Anthony Dorling
David Ayares
Michael A Rees
Jörg D Seebach
Jay A Fishman
Bernhard J Hering
David K C Cooper

Funding

XENOGRAFT TOLERANCE THROUGH MIXED CHIMERISMP01AI045897 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI Megan Sykes · 2000 to 2026
$71.9M
Immunomodulation for Heart Allograft ToleranceU01AI066719 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI PIERSON, RICHARD N · 2005 to 2016
$8.5M
Pig to Non-Human Primate Islet XenograftsU19AI067151 · NIAID · UNIVERSITY OF MINNESOTA · PI HERING, BERNHARD JOSEF · 2005 to 2009
$5.6M
Thromboregulation to Prevent Thrombotic MicroangiopathyU01AI068642 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI COOPER, DAVID KC · 2005 to 2008
$2.7M
Mechanisms of GalTKO Lung Xenograft InjuryU01AI066335 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI PIERSON, RICHARD N · 2005 to 2009
$2.4M
Innate Cellular Lectin-Mediated Binding of Xenogeneic AntigensR01DK066160 · NIDDK · UNIVERSITY OF TOLEDO HEALTH SCI CAMPUS · PI REES, MICHAEL A · 2005 to 2009
$1.3M
Medical Research Council G0801965NIAID NIH HHS P01 AI045897NIAID NIH HHS P01-AI45897NIAID NIH HHS U01 AI066335NIAID NIH HHS U01 AI066719NIAID NIH HHS U01 AI 066719-01NIAID NIH HHS U01 AI068642NIAID NIH HHS U19 AI067151NIAID NIH HHS UO1 AI 066335-01NIAID NIH HHS UO1 AI068642NIDDK NIH HHS R01 DK066160PHS HHS R21 A1074844
6 · The paper itself

Abstract

Xenotransplantation is one promising approach to bridge the gap between available human cells, tissues, and organs and the needs of patients with diabetes or end-stage organ failure. Based on recent progress using genetically modified source pigs, improving results with conventional and experimental immunosuppression, and expanded understanding of residual physiologic hurdles, xenotransplantation appears likely to be evaluated in clinical trials in the near future for some select applications. This review offers a comprehensive overview of known mechanisms of xenograft injury, a contemporary assessment of preclinical progress and residual barriers, and our opinions regarding where breakthroughs are likely to occur.

Indexed as

Transplantation, HeterologousAnimalsAnimals, Genetically ModifiedAntigensBlood CoagulationComplement ActivationGraft RejectionGraft SurvivalHumansImmune ToleranceImmunosuppression TherapyT-LymphocytesAntigens

Identifiers

PMID19796067
PMCPMC2866107

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.